The Most Up-to Date Microsoft070-411Exam Questions 700-505 700-501 648-232 640-911 070-462 3I0-012 070-463 Latest117-202Questions - LPIC Level 2 117-202 Certification RCDD-001 070-685 200-101 070-412 Download Cisco400-101Exams - Free VCE Exams For All 70-243 200-120 100-105 Latest 117-201 Questions - LPIC Level 2 117-201Certification C9530-404 070-480 70-487 300-207 4A0-100 600-199 350-018 070-410 100-101 CCNP Routing and Switching SWITCH300-115Official Cert M70-201 C2020-703 070-347 70-412 70-417 JN0-643 E20-690 70-410 642-747 70-331 70-413 Pass MICROSOFT70-411exam - test questions 352-001 210-260 SY0-401 200-125 300-320 200-310 CISSP PMP 300-075 210-065 Cisco CCNA Collaboration210-060CICD: Welcome to Cisco 70-534 70-532 EX200 1Z0-803 210-451 300-101 Latest HP0-S42 Questions - ASEHP0-S42Certification 300-206 070-346 70-461 HP0-S41 640-916 CompTIA Network+N10-006 EX300 1Z0-434 1Z0-060 C_HANAIMP151 C_TAW12_740 AWS-SYSOPS 70-346 2V0-620 300-070 C_HANATEC151 LatestE05-001Questions - Cloud Architect (EMCCA) JN0-360 2V0-641 642-999 70-697 300-208 FC0-U51 Latest PW0-071 Questions - CWTS PW0-071Certification C_GRCAC_10 IIA-CIA-PART3 642-732 500-260 C_HANAIMP142 98-366 1Z0-047 70-496Microsoft Real Exam Questions - 100% Free VCE Files 70-533 810-403 642-998 70-470 JN0-343 CCNP Wireless642-742New Updated Cisco 642-742 Study 220-802 70-486 642-035 JN0-692 1Z0-470 CAS-002 Cisco 642-883 Dumps |642-883Exam Questions PGMP 200-105 1Z0-051 642-887 070-688 156-215.77 400-351 H12-211Exam Huawei H12-211 Test Questions PDF C2090-930 102-400 70-696 SK0-004 101-400 1Z0-061 ADM-211 300-360 CCNP Data Center642-996Latest Version Cisco 642-996 With New 400-051 70-646 4A0-107 1Z0-574 74-343 700-039 1Z0-435Oracle Business Process Management Suite 1Y0-401 1Y0-201 200-355 74-344 300-135 Download300-370Exam PDF Questions Answers 712-50 070-496 C2090-311 300-080 640-875 AX0-100Axis Communications Real Exam Questions

General News

by Sophiris Admin

In: General News, News, Press Releases

No comments

Share Consolidation in Anticipation of Listing on the NASDAQ Stock Market

San Diego and Vancouver, British Columbia, August 12, 2013 – Sophiris Bio Inc. (TSX: SHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), today announced a 52-for-1 consolidation of its common shares traded on the Toronto Stock Exchange, effective August 9, 2013 (the “Effective Date”).  The purpose of the consolidation is to increase the share price to meet the minimum share price requirements for a potential listing on the NASDAQ stock market.

The share consolidation was approved by the Company’s Board of Directors on August 9, 2013.  The Company’s consolidated common shares are expected to begin trading on the Toronto Stock Exchange when the market opens on August 15, 2013.

Each fifty two (52) common shares issued and outstanding immediately prior to August 9, 2013 will automatically be reclassified, without any action of the holder thereof, into one common share. The share consolidation will affect all of the Company’s common shares outstanding immediately prior to the market opening on August 9, 2013, as well as the number of common shares that may be issued pursuant to options granted under the Company’s equity incentive plan and the exercise prices for such options. In addition, the share consolidation will effect a reduction in the number of shares of common stock issuable upon the exercise of outstanding warrants to purchase common shares and a proportionate increase to the exercise price for such warrants. As a result of the share consolidation, the number of issued and outstanding common shares will be reduced from 163,793,203 to 3,149,869.

No fractional shares will be issued as a result of the share consolidation. Fractional interests of 0.5 or greater will be rounded up to the nearest whole number of shares and fractional interests of less than 0.5 will be rounded down to the nearest whole number of shares.  Registered shareholders of the Company will be receiving a letter of transmittal from the Company’s transfer agent, Computershare Investor Services Inc., as soon as practicable after the effective date of the share consolidation. The letter of transmittal will enable registered shareholders to exchange their old share certificates representing pre-consolidation common shares for new share certificates representing the post-consolidation common shares. Until surrendered, each share certificate representing pre-consolidation common shares will be deemed for all purposes to represent the number of whole post-consolidation common shares to which the holder is entitled as a result of the consolidation.

Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is planning to begin a Phase 3 clinical trial of PRX302 in the second half of 2013 subject to raising additional capital. For more information, please visit www.sophirisbio.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

Lauren Glaser
Investor Relations
The Trout Group
646-378-2972
lglaser@troutgroup.com

James Beesley
Investor Relations
Sequoia Partners
778-389-7715
james@sequoiapartners.ca

Michael Moore
Investor Relations
Equicom Group
619-467-7067
mmore@tmxequicom.com

Jason I. Spark
Canale Communications, Inc.
619-849-6005
jason@canalecomm.com

Download full press release »

070-411 , 700-505 , 700-501 , 648-232 , 640-911 , 070-462 , 3I0-012 , 200-101 , C2020-703 , 070-347 , 070-463 , 070-412 , 117-202 , 400-101 , 70-412 , 70-243 , 70-417 , 200-120 , 100-105 , 117-201 , C9530-404 , 070-480 , 70-487 , 300-207 , JN0-643 , 4A0-100 , 600-199 , E20-690 , 350-018 , 070-410 , 70-410 , 100-101 , 642-747 , 70-331 , 70-413 , 70-411 , 352-001 , 210-260 , SY0-401 , 200-125 , 300-320 , 200-310 , CISSP , 300-115 , PMP , 300-075 , 210-065 , 210-060 , 70-534 , 70-532 , EX200 , 1Z0-803 , 210-451 , 300-101 , HP0-S42 , 300-206 , 070-346 , 70-461 , HP0-S41 , 640-916 , N10-006 , EX300 , 1Z0-434 , 1Z0-060 , C_HANAIMP151 , C_TAW12_740 , AWS-SYSOPS , 70-346 , 2V0-620 , 300-070 , C_HANATEC151 , E05-001 , JN0-360 , 2V0-641 , M70-201 , 642-999 , 70-697 , 300-208 , FC0-U51 , PW0-071 , C_GRCAC_10 , IIA-CIA-PART3 , 642-732 , 500-260 , C_HANAIMP142 , 98-366 , 1Z0-047 , 70-496 , 70-533 , 810-403 , 642-998 , 70-470 , JN0-343 , 642-742 , 220-802 , 70-486 , 642-035 , JN0-692 , 1Z0-470 , CAS-002 , 642-883 , PGMP , 200-105 , 1Z0-051 , 642-887 , 070-688 , 156-215.77 , RCDD-001 , 400-351 , H12-211 , C2090-930 , 102-400 , 70-696 , 070-685 , SK0-004 , 101-400 , 1Z0-061 , ADM-211 , 300-360 , 642-996 ,